接受双联抗血小板治疗的冠心病患者缺血和出血风险评估研究进展

Research progress of risk assessment of ischemia and bleeding in patients with coronary heart disease receiving dual antiplatelet therapy

冠心病患者的双联抗血小板治疗(DAPT)近年来一直是热议的话题。随着新型P2Y_(12)受体抑制剂的问世,DAPT的升阶和降阶成为目前研究的热点,而上述问题的核心则是对该群体缺血及出血风险的评估。本综述旨在结合最新国内外研究及指南,以各种危险因素的评估系统为切入点,探讨患者个体化动态风险评估标准,以期对应用DAPT患者的全程个体化治疗提供新的思路。

Dual antiplatelet therapy(DAPT)for patients with coronary heart disease has been a hot topic in recent years.With the advent of new P2Y12 receptor inhibitor,the escalation and deescalation of DAPT has gradually become a popular point in current research.The core of the issue is the assessment of the risk of ischemia and bleeding for the patients with coronary heart disease.This review aims to discuss the individualized and dynamic risk assessment criteria for the above patients based on the latest domestic and foreign research and guidelines combining with various risk factor assessment system as the entry point,in order to provide a new thought for the entire individualized treatment of patients with DAPT.